Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports.
We present two cases of primary limited cutaneous perineal and genital extramammary Paget's disease (EMPD) that were successfully treated with imiquimod 5% cream. Clinical and histologic cure was confirmed after 7.5 to 12 weeks of monotherapy. Treatment-associated morbidity is minimal compared with more invasive therapies, and self-application by the patient improves convenience and appeal. Imiquimod may offer a minimally invasive and promising therapeutic option for the treatment of limited cutaneous EMPD. The diagnosis and management of EMPD and the current literature regarding imiquimod therapy are reviewed.
Zampogna
Jennifer C
JC
Division of Dermatology and Cutaneous Surgery, University of Florida College of Medicine, Gainesville, 32610-0277, USA.
Flowers
Franklin P
FP
Roth
William I
WI
Hassenein
Ashraf M
AM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000627:therapeutic use; D000287:Administration, Topical; D000368:Aged; D000634:Aminoquinolines / Q000008:administration & dosage* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010145:Paget Disease, Extramammary / Q000175:diagnosis / Q000188:drug therapy*; D010502:Perineum; D012611:Scrotum; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D007369:Interferon Inducers; D000077271:Imiquimod